Sarah Hoover supports clients with research and analysis spanning a variety of healthcare sectors and stakeholders.
She applies her pre-medical and research background to provide support for a wide range of client projects.
Prior to joining Avalere, Sarah conducted research on the importance of public and stakeholder engagement practices for creating scientific policy, specifically when developing guidelines on the use of gene editing technologies.
Sarah has a BS degree in biology from Wake Forest University. She is currently working to increase her formal education of the health policy landscape by pursing a MS in Health and the Public Interest at Georgetown University.
Authored Content
Drug manufacturers can use real-world evidence (RWE) before and after approval to advance product development and adoption.
Telehealth solutions aimed at enhancing quality, cost, and equity require greater investment in evidence generation and clinical practice guideline development.